Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Rendo

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Pediatrics|December 5, 2002
Erythropoietin and preemiesHugo Donato, Pablo Rendo, Luis Prudent, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|July 22, 2015
Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalitiesPablo Rendo, Lynne Smith, Hsiao-Yu Lee, et al.
Clinical Therapeutics|March 13, 2016
Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia BJoan M Korth-Bradley, Pablo Rendo, Lynne Smith, et al.
Clinical and Translational Science|March 26, 2018
Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia AJoan Korth-Bradley, Jeremy Rupon, Anna Plotka, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|September 24, 2013
Factors that influence the bleeding phenotype in severe hemophilic patientsPablo Rendo, Frank Shafer, Joan M Korth-Bradley, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|November 15, 2017
Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfaPablo Rendo, Janice Lamb, Lynne Smith, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 25, 2021
Once-weekly prophylaxis regimen of nonacog alfa in patients with hemophilia B: an analysis of timing of bleeding event onsetBartholomew J Tortella, Marcus E Carr, Pablo Rendo, et al.
Journal of Clinical Gastroenterology|December 18, 2001
The role of transfusion-transmitted virus in patients undergoing hemodialysisRodolfo Valtuille, Fernando Frankel, Federico Gómez, et al.
European Journal of Haematology|June 26, 2024
Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B-LONG studyBeatrice Nolan, Michael Recht, Pablo Rendo, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 5, 2020
Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding rates in paediatric patients with severe haemophilia AMark P Smith, Jeremy Rupon, Yasser Wali, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Pediatrics|December 5, 2002
Erythropoietin and preemiesHugo Donato, Pablo Rendo, Luis Prudent, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|July 22, 2015
Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalitiesPablo Rendo, Lynne Smith, Hsiao-Yu Lee, et al.
Clinical Therapeutics|March 13, 2016
Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia BJoan M Korth-Bradley, Pablo Rendo, Lynne Smith, et al.
Clinical and Translational Science|March 26, 2018
Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia AJoan Korth-Bradley, Jeremy Rupon, Anna Plotka, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|September 24, 2013
Factors that influence the bleeding phenotype in severe hemophilic patientsPablo Rendo, Frank Shafer, Joan M Korth-Bradley, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|November 15, 2017
Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfaPablo Rendo, Janice Lamb, Lynne Smith, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 25, 2021
Once-weekly prophylaxis regimen of nonacog alfa in patients with hemophilia B: an analysis of timing of bleeding event onsetBartholomew J Tortella, Marcus E Carr, Pablo Rendo, et al.
Journal of Clinical Gastroenterology|December 18, 2001
The role of transfusion-transmitted virus in patients undergoing hemodialysisRodolfo Valtuille, Fernando Frankel, Federico Gómez, et al.
European Journal of Haematology|June 26, 2024
Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B-LONG studyBeatrice Nolan, Michael Recht, Pablo Rendo, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 5, 2020
Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding rates in paediatric patients with severe haemophilia AMark P Smith, Jeremy Rupon, Yasser Wali, et al.
Pageof 2